Brii Biosciences Limited
BRIBF
$0.2406
$0.00944.07%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -178.67% | -49.30% | 21.72% | 48.15% | 65.42% |
| Total Depreciation and Amortization | -45.79% | -35.39% | -26.84% | -19.70% | -12.62% |
| Total Amortization of Deferred Charges | 0.54% | -0.36% | -3.63% | -3.63% | -3.63% |
| Total Other Non-Cash Items | 155.30% | 116.24% | 54.27% | -172.17% | -680.93% |
| Change in Net Operating Assets | 57.92% | 13.60% | -51.20% | -51.20% | -51.20% |
| Cash from Operations | 38.55% | 30.42% | 22.89% | 5.86% | -13.72% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 852.68% | 170.20% | 130.41% | 114.76% | 91.81% |
| Cash from Investing | 849.97% | 170.02% | 130.38% | 114.74% | 91.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 27.65% | 19.93% | 12.19% | 3.34% | -6.03% |
| Issuance of Common Stock | -70.39% | -96.87% | -97.94% | -97.72% | -97.60% |
| Repurchase of Common Stock | 81.07% | 24.89% | -71.39% | -71.39% | -71.39% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -378.95% | -221.27% | -96.64% | -16.73% | 41.95% |
| Cash from Financing | 15.48% | -13.35% | -61.33% | -120.19% | -241.66% |
| Foreign Exchange rate Adjustments | -93.97% | -98.16% | -98.43% | -97.47% | -96.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 170.59% | 120.99% | 106.57% | 87.14% | 57.37% |